-

Ikonisys: The 2023 Annual Report Is Now Available

PARIS--(BUSINESS WIRE)--Regulatory News:

Ikonisys SA (Euronext Growth Paris: ALIKO), a leading company in early and accurate cancer diagnosis through cutting-edge and fully automated solutions for medical analysis laboratories, hereby announces that its 2023 Annual Financial Report, for the year ended December 31, 2023, is now available and was filed with the Autorité des Marchés Financiers (AMF).

The document is available on the Company’s investor website: www.ikonisys-finance.com (in the Documentation > Financial report section).

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys-finance.com

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

Contacts

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

Ikonisys SA

BOURSE:ALIKO

Release Versions

Contacts

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

More News From Ikonisys SA

Ikonisys finalized a Capital Increase and Debt Conversion of EUR 2.72 million with strategic investment from Avantgarde Srl and Alberto Previtali

PARIS--(BUSINESS WIRE)--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “Issuer”), today announces a capital increase in cash for a total of €1.5 million by way of a private placement, and the request to convert €1.22 million of existing debt into capital. The total amount of the round is therefore of €2.72 million. Strategic Invest...

Ikonisys: Cytofast Auto: The First Fully Automatic Universal Monolayer Cytology Processor Is Born

PARIS--(BUSINESS WIRE)--Regulatory News: Hospitex international, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces the start of the design of Cytofast Auto, the first fully automated and—most importantly—universal LBC (Liquid Based Cytology) processor, a project that opens a new phase not only for Hospitex, but for the entire global cytology sector. A long-awaited revolution LBC...

Ikonisys: Hospitex Initiates International Dialogues for Pilot Projects in Oncology Diagnostics Following ADB Delegation Visit

PARIS--(BUSINESS WIRE)--Regulatory News: Hospitex, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces that it is preparing the pilot project of Urine24 in the Far East, following ADB (Asian Bank Development) Delegation Visit. The visit took place as part of the Health Study Tour, an initiative promoted by the Italian Ministry of Economy and Finance (MEF) in collaboration with the...
Back to Newsroom